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Abstract 
The inaugural issue of “SunText Review of Endocrine Care” has been published. As the sun and moon shine during the day and at  
night, this journal will illuminate the world's medical community for long. When looking back the history of human being, the 
evolution of metabolic programs was observed. Under favourable and unfavourable environment, anabolic and maintenance program 
were continued, respectively. Food deficiency resulted in elevated ketone bodies (KB), which became important energy producing 
system in addition to glucose metabolism. Recent topics concerning KB include beneficial mechanism for cardiovascular disease, 
efficacy for neurodegenerative diseases and supplementation with exogenous KB. 
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Editorial Article 
Congratulations for the inaugural issue of “SunText Review of 
Endocrine Care” [1]. As the sun and moon shine during the day 
and at night, this journal will illuminate the world's medical 
community for long. When looking back the long history, human 
beings have showed evolution for long years associated with 
metabolic change [2]. In favorable environment, growth and 
reproduction programs had been continued, which were anabolic 
metabolism. Under unfavorable environment, maintenance 
programs were engaged including dormancy and defence. 
Dormancy is induced by nutrient shortage relying on energy 
preserving catabolic metabolism. Defense is induced by infections 
and other aggressive factors with supporting anabolic metabolism 
[2]. 
Regarding human evolution, metabolic programs have changed 
during 4-7 million years [2]. There has been comparative 
perspective on two situations on fasting and binge eating [3]. 
Food deficiency resulted in elevated ketone bodies (KB), 
enhanced cognition, synaptic plasticity, neurogenesis, and neuro 
protection. This mechanism demonstrates optimal cognitive 
function and resistance to injury and illness. On the other hand, 
the latter has been recently observed in medical and health issues 
related to non-communicable diseases (NCDs) worldwide. Food 
abundance results in increased insulin resistance and cognitive 
complacency, leading to synaptic dysfunction, neurogenesis 
disorders, and neuro degeneration. This mechanism demonstrates 
suboptimal cognition and vulnerability to injury and disease [3]. 
From historical and medical points of view, recent topics would 
be described in this article concerning diabetes, KB, β-
hydroxybutyrate (βHB), fatty acids, low carbohydrate diet (LCD), 
ketogenic diet (KD) and cardiovascular disease.  
As an important study for diabetes, EMPA-REG OUTCOME has 
been known. Empagliflozin showed slower progression of CKD 
and lower rates of clinical events than control [4]. Regarding the 
protection efficacy for renal problem, KB seemed to be involved 
in the mechanism [5]. During the treatment of SGLT2i, rather 
persistent and mild hyperketonemia would be observed. In such 
circumstances, β-HB is taken up freely especially by the heart and 
is oxidized in predominance to free fatty acids (FFA). This 
automatic selection may improve the transduction of oxygen 
consumption for the efficient work at the mitochondrial level. 
Furthermore, the cardiorenal beneficial mechanism of 
empagliflozin would be from a shift in myocardial and renal fuel 
metabolism. This change seems to be from fat and glucose 
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oxidation with inefficient energy of heart and kidney, toward KB 
system with energy-efficient super fuel [6].  
When insulin levels decrease or exercise is performed for a long 
time, free fatty acids (FFA) are mobilized from adipose tissue into 
the blood. From FFA, liver produces KB that exhibit beneficial 
effects on the heart with heart failure situation. Regarding the 
metabolism of KB, the fuel profiles of the heart and leg were 
investigated [7]. The human arterial-venous metabolomics were 
measured by the simultaneous blood sampling from radial artery, 
coronary sinus and femoral vein. As a result, the leg obtained 
about 90% of carbons from KB and glucose. In contrast, the leg 
released most carbons as lactate, FFA, and amino acids. In detail, 
approximately half of released FFA was C18:2 (linoleate), 
essential FFA, suggesting active lipolysis from adipose tissue. On 
the other hand, the heart showed that most carbons are from 
FFAs. KB were accounted for about 15% of carbon uptake in the 
heart, and acetate were about 2%, which is most abundant short-
chain fatty acid [7]. As to clinically important point, the energy 
source would be switched from FFA to KB in the heart disease 
such as heart failure.  
Thus, in heart failure, KB metabolism in the heart would be 
stimulated. It is not completely clarified whether this finding 
means protective to the heart, or conversely harmful to 
remodeling. According to the recent report, continuous 
intravenous infusion of KB improved cardiac output without 
increasing energy and oxygen demand [8]. In other words, KB 
can improve cardiac function without imposing a burden on 
cardiomyocytes. Furthermore, continuous intravenous infusion of 
KB has been reported to improve cardiac blood flow [9]. Thus, 
KB are considered to have a potential therapeutic effect on heart 
diseases centered on heart failure. Therefore, measures to increase 
the blood KB level may be effective.  
As to cardiac function, hyperketonemia would bring several 
mechanisms with beneficial effects for protecting human organs 
[10]. There are 10 related factors in the following: i) elevation of 
cardiac energetics, endothelial function mitochondrial function, ii) 
reduction of cardiac remodelling, inflammation, oxidative stress, 
Histone deacetylase (HDAC, iii) related mechanism of blood 
pressure, body weight, blood glucose and lipid profile.  
In addition to the above-mentioned cardiovascular system, KB 
have also been reported to be effective against neurodegenerative 
diseases. KD has been known to have historically efficacy for 
epilepsy and GLUT-1 deficiency [11,12]. It is also expected to be 
effective against mild cognitive impairment (MCI), Alzheimer's 
disease, and Parkinson's disease [13]. There was an impressive 
report that KB was effective against acromegaly, which is one of 
the endocrine diseases [14]. From the above, it can be considered 
that the protective effect of ketone bodies on brain cells can be 
observed.  
Such an investigation would provide some answer for various 
inquiries. One question would be which is more effective, i) 
stabilization of glycemic fluctuations by LCD or ii) maintenance 
of hyperketonemia by some agent [15]. It has been reported that 
supplementation with ketone esters improved early insulin 
secretory response for 75gOGTT with alleviation of impaired 
glucose tolerance (IGT) [16]. For the background of this 
mechanism, hyperketonemia itself may contribute to the 
stabilization of glycemic fluctuations. From meta-analysis of 
RCTs, LCD showed better result than KD [17]. This reason 
would be probably easy continuation for the patients. 
Consequently, it would be a gospel method, if diabetic patient can 
have some medicine of KB precursors, associated with loose 
dietary restriction life.  
In recent report, supplementation with exogenous βHB was 
provided [18]. Subjects included 22 healthy male and female 
adolescents, who consumed βHB 3.75g or maltodextrin placebo 
twice daily for 90 days. The analyzed factors were blood test, 
bone density, emotional intelligence and happiness surveys and 
blood pressure checked at 0, 45 day and 90 day. The result was 
well-tolerated and safe in the case of adolescence subjects [18].  
In summary, several impressive information was commented. 
This report will hopefully become a reference for clinical practice 
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